Results for
""Drugs, Investigational""[mesh_terms]

Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years.

Thomas E Lackner, Anna M Hackman

Pharmacotherapy 2006;26(1):68-94

New Drugs for Atherosclerosis.

Caroline S Bruikman, Robert M Stoekenbroek, G Kees Hovingh, John P Kastelein

The Canadian journal of cardiology 2017;33(3):350-357

Investigational drugs for the treatment of acromegaly: new agents to transform therapy.

Rosario Pivonello, Annamaria Colao, Rosa Pirchio, Renata S Auriemma, Alice Vergura

Expert opinion on investigational drugs 2024;33(5):509-522

Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301.

Jasmine A Fels, Gabriella Casalena, Csaba Konrad, Holly E Holmes, Ryan W Dellinger, Giovanni Manfredi

Human molecular genetics 2022;31(20):3458-3477

Oxipurinol: alloxanthine, Oxyprim, oxypurinol.

Drugs in R&D 2004;5(3):171-5

Peripheral channelopathies as targets for potassium channel openers.

M J Dunne, K Lawson

Expert opinion on investigational drugs 2002;10(7):1345-59

Investigational drugs for eating disorders.

Scott Crow, Eric Brown

Expert opinion on investigational drugs 2003;12(3):491-9

Medication management of irritable bowel syndrome.

Milap C Nahata, Katy E Trinkley

Digestion 2015;89(4):253-67

Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs.

Angel L M de Francisco

Expert opinion on pharmacotherapy 2007;7(16):2215-24

Potassium channel modulators and schizophrenia: an overview of investigational drugs.

Mohammed Malik, Meghan Musselman, Eric Huynh, Rachana Kelshikar, Eric Lee, Justin Faden

Expert opinion on investigational drugs 2023;32(6):471-477

Pharmacologic therapy for obesity.

John N Udall, Dolleen M Licciardi, Frank Svec

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 2005;157 Spec No 1():S56-64

Current and future trends in the lipid lowering therapy.

Bogusław Okopień, Łukasz Bułdak, Aleksandra Bołdys

Pharmacological reports : PR 2017;68(4):737-47

Current options and investigational drugs for the treatment of eosinophilic esophagitis.

Sonsoles Tamarit-Sebastian, Francisco Miguel Ferrer-Soler, Alfredo J Lucendo

Expert opinion on investigational drugs 2022;31(2):193-210

Modulation of apoptosis as a target for liver disease.

Sören T Eichhorst

Expert opinion on therapeutic targets 2006;9(1):83-99

Ethnobotany and its role in drug development.

M Heinrich

Phytotherapy research : PTR 2001;14(7):479-88